Eye insert could ease allergy symptoms for contact lens wearers
NCT ID NCT04418999
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tested a dexamethasone eye insert placed by a doctor against a standard steroid gel for treating allergy and dry eye symptoms in 36 people with keratoconus who wear gas permeable contact lenses. The goal was to see if the insert improves signs like eyelid bumps and eye dryness better than the gel. Results may point to a simpler treatment option that doesn't require daily drops.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- dexamethasone ophthalmic insert
- What this could lead to
- If it works, this could offer a more convenient, doctor-administered treatment for allergy and dry eye symptoms in keratoconus patients who wear contact lenses.
- What could go wrong
- This is a very early, small trial with only 36 participants, so results may not be conclusive. The insert may not work better than the standard gel, and there are risks like increased eye pressure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Early phase 1
The earliest testing in people: a first look at safety, in a very small group.
- Participants
-
36 people
The number who actually took part.
- Started
-
Sep 2020
- Finished
-
Dec 2021
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * 18 years of age or older * Bilateral Keratoconus * Bilateral RGP contact lenses * Bilateral allergic conjunctivitis as determined by the Papillae Efron Scale score of at least 1 and symptoms of itching * Bilateral underlying dry eye disease as determined by the NEI Fluorescein Staining Scale score of at least 1 and a TBUT of less than 10 and must correlate with dryness on OSDI Exclusion Criteria: * Patients under the age of 18. * Pregnancy (must be ruled out in women of child-bearing age with pregnancy test) * Active infectious systemic disease * Active infectious ocular or extraocular disease * Obstructed nasolacrimal duct in the study eye(s) * Hypersensitivity to dexamethasone * Patients being treated with immunomodulating agents in the study eye(s) * Patients being treated with immunosuppressants and/or oral steroids Patients with severe disease that warrants critical attention, deemed unsafe for the study by the investigator
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Allergic conjunctivitis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Illinois Eye Institute
Chicago, Illinois, 60616, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Shorter eye treatment put to the test against standard crosslinking
- Shorter UV treatment for keratoconus put to the test
- Can a 13-Minute eye exercise routine ease screen strain?
- Insulin eye drops put to the test for faster corneal healing
- Gel plug in tear duct tested to keep eyes moist after cataract surgery
- Eye scans could spot hidden vision risk in down syndrome